Research programme: farnesoid X receptor agonists - Poxel

Drug Profile

Research programme: farnesoid X receptor agonists - Poxel

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Poxel
  • Developer ENYO Pharma; Poxel
  • Class
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B; Type 2 diabetes mellitus

Most Recent Events

  • 21 Jul 2016 Preclinical development is ongoing for Type-2 diabetes mellitus in France (Poxel pipeline, July 2016)
  • 28 May 2009 Preclinical trials in Type-2 diabetes mellitus in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top